1. Home
  2. IHS vs COGT Comparison

IHS vs COGT Comparison

Compare IHS & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IHS Holding Limited

IHS

IHS Holding Limited

HOLD

Current Price

$7.52

Market Cap

2.4B

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$39.00

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IHS
COGT
Founded
2001
2014
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.3B
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
IHS
COGT
Price
$7.52
$39.00
Analyst Decision
Buy
Buy
Analyst Count
7
13
Target Price
$9.32
$28.08
AVG Volume (30 Days)
1.0M
4.7M
Earning Date
11-12-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.37
N/A
Revenue
$1,765,825,000.00
N/A
Revenue This Year
$3.49
N/A
Revenue Next Year
$2.77
N/A
P/E Ratio
$5.47
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.90
$3.72
52 Week High
$8.00
$43.73

Technical Indicators

Market Signals
Indicator
IHS
COGT
Relative Strength Index (RSI) 68.70 71.38
Support Level $6.93 $38.10
Resistance Level $7.66 $43.73
Average True Range (ATR) 0.24 2.22
MACD 0.10 -0.53
Stochastic Oscillator 89.92 53.39

Price Performance

Historical Comparison
IHS
COGT

About IHS IHS Holding Limited

IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: